← Back to Search
Anti-tumor antibiotic
Good Choice of pALliative Chemotherapy to Patient With Pancreatic Cancer ; GemcitAbine Therapy vs FOLFORINOX therapY (GALAXY Trial)
Seoul, Korea, Republic of
N/A
Recruiting
Research Sponsored by Boryung Pharmaceutical Co., Ltd
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, month 2, month 6, month 12
Awards & highlights
No Placebo-Only Group
Summary
The study objectives are to find out: 1) palliative chemotherapy patterns and prognosis in patients with locally advanced or metastatic pancreatic cancer in Korea's real clinical settings, and 2) reasons adopted by clinicians in choosing therapeutic drugs.
See full description
Eligible Conditions
- Pancreatic Cancer
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ baseline, month 2, month 6, month 12
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, month 2, month 6, month 12
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Chemotherapy patterns(Type of the first-line palliative chemotherapy)
Chemotherapy patterns(Type of the second-line palliative chemotherapy)
Overall Survival (OS)
+1 moreSecondary study objectives
Eastern Cooperative Oncology Group Performance Status (ECOG PS) scores
Quality of Life Assessment
The best response
+1 moreOther study objectives
Adverse drug reactions(ADR)
Adverse drug reactions(ADR) caused delay/discontinuation of planned chemotherapy
Serious adverse drug reactions(SADR)
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Find a Location
Who is running the clinical trial?
Boryung Pharmaceutical Co., LtdLead Sponsor
146 Previous Clinical Trials
116,048 Total Patients Enrolled